Arsenic-Containing Qinghuang Powder (青黄散) Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy

Teng FAN; Ri-cheng QUAN; Wei-yi LIU; Hai-yan XIAO; Xu-dong TANG; Chi LIU; Liu LI; Yan LV; Hong-zhi WANG; Yong-gang XU; Xiao-qing GUO; Xiao-mei HU

doi:10.1007/s11655-019-3050-6

Your Location：

Home >

Browse articles >

Arsenic-Containing Qinghuang Powder (青黄散) Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy

Original Article | Updated：2021-08-23

- Arsenic-Containing Qinghuang Powder (青黄散) Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy
- Arsenic-Containing Qinghuang Powder (青黄散) Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy
- Chinese Journal of Integrative Medicine 2020年26卷第5期页码：339-344
- Affiliations：
  
  1.Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing (100091), China
  2.Graduate School, China Academy of Chinese Medical Sciences, Beijing (100700), China
- Author bio：
  
  Correspondence to: Prof. HU Xiao-mei, E-mail:huxiaomei_2@163.com
- Funds：
  
  Special Grants of Clinical Research Base of Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine(JDZX2012180)
- DOI：10.1007/s11655-019-3050-6
  中图分类号：
- 纸质出版日期：2020-05-01，
  
  网络出版日期：2019-12-17，
  
  录用日期：2018-10-27
Scan for full text
Teng FAN, Ri-cheng QUAN, Wei-yi LIU, 等. Arsenic-Containing Qinghuang Powder (青黄散) Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy[J]. Chinese Journal of Integrative Medicine, 2020,26(5):339-344.

Teng FAN, Ri-cheng QUAN, Wei-yi LIU, et al. Arsenic-Containing Qinghuang Powder (青黄散) Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy[J]. Chinese Journal of Integrative Medicine, 2020,26(5):339-344.
Teng FAN, Ri-cheng QUAN, Wei-yi LIU, 等. Arsenic-Containing Qinghuang Powder (青黄散) Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy[J]. Chinese Journal of Integrative Medicine, 2020,26(5):339-344. DOI： 10.1007/s11655-019-3050-6.

Teng FAN, Ri-cheng QUAN, Wei-yi LIU, et al. Arsenic-Containing Qinghuang Powder (青黄散) Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy[J]. Chinese Journal of Integrative Medicine, 2020,26(5):339-344. DOI： 10.1007/s11655-019-3050-6.

摘要

Abstract

Objective:

To analyze the overall survival (OS) of elderly acute myeloid leukemia (AML) patients treated with oral arsenic-containing Qinghuang Powder (青黄散

QHP) or low-intensity chemotherapy (LIC).

Methods:

Forty-two elderly AML patients treated with intravenous or subcutaneous LIC (1 month for each course

at least 3 courses) or oral QHP (3 months for each course

at least 2 courses) were retrospectively analyzed from January 2015 to December 2017. The main endpoints of analysis were OS and 1-

3-year OS rates of patients

respectively. And the adverse reactions induding bone marrow suppression

digestive tract discomfort and myocardia injury were observed.

Results:

Out of 42 elderly AML patients

22 received LIC treatment and 20 received QHP treatment

according to patients' preference. There was no significant difference on OS between LIC and QHP patients (13.0 months vs. 13.5 months

0.05). There was no significant difference on OS rates between LIC and QHP groups at 1 year (59.1% vs. 70.0%)

2 years (13.6% vs. 15%)

and 3 years (4.6% vs. 5.0%

all

0.05). Furthermore

there was no significant difference of OS on prognosis stratification of performance status

2 (12 months vs. 12 months)

age

75 year-old (12.0 months vs. 12.5 months)

hematopoietic stem cell transplant comorbidity index

2 (12 months vs. 13 months)

poor cytogenetics (12 months vs. 8 months)

and diagnosis of secondary AML (10 months vs. 14 months) between LIC and QHP patients (

0.05).

Conclusion:

QHP may be an alternative treatment for elderly AML patients refusing LIC therapy.

关键词

Keywords

acute myeloid leukemiaQinghuang PowderRealgararsenicelderly patientChinese medicine

references

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia